Trial Profile
A PHASE I OPEN-LABEL PHARMACOKINETICS AND SAFETY STUDY OF TALAZOPARIB (MDV3800) IN PATIENTS WITH ADVANCED SOLID TUMORS AND NORMAL OR VARYING DEGREES OF RENAL IMPAIRMENT
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Talazoparib (Primary)
- Indications Advanced breast cancer; Biliary cancer; Bladder cancer; Colon cancer; Endometrial cancer; Gastric cancer; Lymphoma; Ovarian cancer; Prostate cancer; Sarcoma; Soft tissue sarcoma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Pfizer
- 09 Mar 2021 Results published in the Clinical Pharmacokinetics
- 25 Jun 2019 Status changed from recruiting to completed.
- 05 Nov 2018 Planned End Date changed from 29 Jan 2019 to 24 May 2019.